Xeljanz Special Investigation for Long-term Use in UC Patients

Pfizer

Status: Completed

Conditions: Ulcerative Colitis

Study type: Observational

Funder types: Industry

Identifiers

NCT03643211

A3921248

Details and patient eligibility

About

Secondary data collection study: safety and effectiveness of Xeljanz in UC patients under Japanese medical practice

Full description

This investigation aims to examine the safety and effectiveness of Xeljanz in post-marketing clinical settings when it is administered chronically to patients with ulcerative colitis, based on the approval conditions.

Enrollment: 2,016 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with ulcerative colitis treated with XELJANZ
• Patients naive to XELJANZ in the treatment of ulcerative colitis

Exclusion criteria

• None

Trial design